Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase

Guan, Xiuwen; Chen, Jie; Hu, Yingying; Lin, Lin; Sun, Pingjie; Tian, Huayu; Chen, Xuesi

doi:10.1016/j.biomaterials.2018.04.039

Cited by 107 publications

(92 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To this end, engineering functional nanomaterials is of critical importance to promote translocation of payloads from endosomes/lysosomes into cytosol, that is, endosome/lysosome escape. Initial attempts incorporate cationic polymers, such as PEI and poly( l ‐lysine) (PLL), in nanoparticle modification, which normally leads to rapid water influx into the lysosome to swell and finally burst it, a phenomenon called the “proton sponge effect.”…”

Section: Nanomaterials For Target Deliverymentioning

confidence: 99%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

124

View full text Add to dashboard Cite

Cancer immunotherapy is a promising cancer terminator by directing the patient's own immune system in the fight against this challenging disorder. Despite the monumental therapeutic potential of several immunotherapy strategies in clinical applications, the efficacious responses of a wide range of immunotherapeutic agents are limited in virtue of their inadequate accumulation in the tumor tissue and fatal side effects. In the last decades, increasing evidences disclose that nanotechnology acts as an appealing solution to address these technical barriers via conferring rational physicochemical properties to nanomaterials. In this Review, an imperative emphasis will be drawn from the current understanding of the effect of a nanosystem's structure characteristics (e.g., size, shape, surface charge, elasticity) and its chemical modification on its transport and biodistribution behavior. Subsequently, rapid‐moving advances of nanoparticle‐based cancer immunotherapies are summarized from traditional vaccine strategies to recent novel approaches, including delivery of immunotherapeutics (such as whole cancer cell vaccines, immune checkpoint blockade, and immunogenic cell death) and engineered immune cells, to regulate tumor microenvironment and activate cellular immunity. The future prospects may involve in the rational combination of a few immunotherapies for more efficient cancer inhibition and elimination.

show abstract

Section: Nanomaterials For Target Deliverymentioning

confidence: 99%

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu

Zhang

2019

Small

124

View full text Add to dashboard Cite

show abstract

“…The transfer of CCR7 pDNA into DCs can help them migrate to lymph nodes and boost antigen presentation. Other typical strategies use nucleic acid to active DCs directly; for example, CpG has been reported many times in recent years …”

Section: Therapeutic Genes Targeting the Tumor Microenvironmentmentioning

confidence: 99%

“…On the other hand, considering the vital role of the tumor microenvironment in tumorigenesis and metastasis, choosing appropriate therapeutic genes targeting the main problems in the tumor microenvironment, such as vigorous tumor cells, scarce tumor antigen, immune suppressive cytokines and checkpoints, will have great potential for cancer gene therapy …”

Section: Introductionmentioning

confidence: 99%

“…24 On the other hand, considering the vital role of the tumor microenvironment in tumorigenesis and metastasis, choosing appropriate therapeutic genes targeting the main problems in the tumor microenvironment, such as vigorous tumor cells, scarce tumor antigen, immune suppressive cytokines and checkpoints, will have great potential for cancer gene therapy. 22,[25][26][27] For gene therapy, carriers and therapeutic genes comprise two core elements that dictate the treatment efficiency. Based on our knowledge of the tumor microenvironment, the design of stimuliresponsive nanocarriers can improve gene delivery efficiency.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Tumor microenvironment as the “regulator” and “target” for gene therapy

Chen

Feng

et al. 2019

The Journal of Gene Medicine

Self Cite

View full text Add to dashboard Cite

In this review, we focus on strategies for designing functional nano gene carriers, as well as choosing therapeutic genes targeting the tumor microenvironment. Gene mutations have a great impact on the occurrence of cancer. Thus, gene therapy plays a major role in cancer therapy and has the potential to cure cancer. Well‐designed gene therapy largely relies on effective gene carriers, which can be divided into viral carriers and non‐viral carriers. A gene carrier delivers functional genes to their intracellular target and avoids nucleic acids being degraded by nucleases in the serum. Most conventional cancer gene therapies only target cancer cells and do not appear to be sufficintly efficient to pass clinical trials. Accumulating evidence has shown that extending the therapeutic strategies to the tumor microenvironment, rather than the tumor cell itself, can allow more options for achieving robust anti‐cancer efficiency. In addition, unusual features between tumor microenvironment and normal tissues, such as a lower pH, higher glutathione and reactive oxygen species concentrations, and overexpression of some enzymes, facilitate the design of smart stimuli‐responsive gene carriers regulated by the tumor microenvironment. These carriers interact with nucleic acids and then form stable nanoparticles under physiological conditions. By regulation of the tumor microenvironment, stimuli‐responsive gene carriers are able to change their properties and achieve high gene delivery efficiency. Considering the tumor microenvironment as the “regulator” and “target” when designing gene carriers and choosing therapeutic genes shows significant benefit with respect to improving the accuracy and efficiency of cancer gene therapy.

show abstract

“…Lastly, TLR9 recognizes unmethylated CpG oligodeoxynucleotides and promotes IL-6 secretion and consequent B cell activation (158)(159)(160)(161)(162)(163)(164)(165)(166)(167)(168). It has been demonstrated that enhancement of TLR9 receptors augment activity of antigen-presenting cells in neonates (93, 102, 169).…”

Section: Toll-like Receptors Agonistsmentioning

confidence: 99%

Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections

2019

View full text Add to dashboard Cite

Well-adapted pathogens have evolved to survive the many challenges of a robust immune response. Defending against all host antimicrobials simultaneously would be exceedingly difficult, if not impossible, so many co-evolved organisms utilize immunomodulatory tools to subvert, distract, and/or evade the host immune response. Bordetella spp. present many examples of the diversity of immunomodulators and an exceptional experimental system in which to study them. Recent advances in this experimental system suggest strategies for interventions that tweak immunity to disrupt bacterial immunomodulation, engaging more effective host immunity to better prevent and treat infections. Here we review advances in the understanding of respiratory pathogens, with special focus on Bordetella spp., and prospects for the use of immune-stimulatory interventions in the prevention and treatment of infection.

show abstract

Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase

Cited by 107 publications

References 52 publications

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Tumor microenvironment as the “regulator” and “target” for gene therapy

Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections

Contact Info

Product

Resources

About